News from hcplive.comFollowNews from hcplive.comSee all of hcplive.com news coverage in one place. Discover how hcplive.com’s media bias informs their coverage and compare with thousands of other news outlets.Ground News has come across 850 headlines reported on by hcplive.com during the past 3 months. hcplive.com’s aggregated media bias check is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is hcplive.com credible or reliable? Our Factuality score answers both of those questions. When it comes to hcplive.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.Follow See all of hcplive.com news coverage in one place. Discover how hcplive.com’s media bias informs their coverage and compare with thousands of other news outlets. Ground News has come across 850 headlines reported on by hcplive.com during the past 3 months. hcplive.com’s aggregated media bias check is . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Is hcplive.com credible or reliable? Our Factuality score answers both of those questions. When it comes to hcplive.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check. Information about hcplive.comWhere is hcplive.com located?hcplive.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top hcplive.com NewsUnited States · United StatesPress Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - Regeneron Pharmaceuticals (NASDAQ:REGN)100% Center coverage: 1 sourcesDupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade…See the StoryChicago, IL · ChicagoAblation Bests Drugs for Ventricular Tachycardia After Heart Attack100% Center coverage: 1 sourcesCHICAGO -- For patients with ventricular tachycardia (VT) and ischemic cardiomyopathy, going right to catheter ablation improved outcomes compared withSee the StoryVaccinations · DenmarkNUDGE-FLU Analysis Finds History of Heart Attack Increases Effectiveness of CV Gain Frame LetterElectronic messages highlighting cardiovascular benefits of flu shots increased vaccination rates by 1.8% in heart attack survivors.See the StoryLatest News StoriesTopics Most Covered by hcplive.comHealthFDADiabetesArtificial IntelligenceCoronavirusHealthFDADiabetesSources Covering Similar Topicsdermatologytimes.comPharmacy TimesMedPage Todaypipelinereviewcontemporarypediatrics.comdermatologytimes.comPharmacy TimesMedPage TodaySuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
